NBI 1117570
Alternative Names: Dual M1/M4 agonist - Neurocrine Biosciences; Dual muscarinic M1/M4 agonist - Nxera Pharma; NBI-1117570; NBI-570Latest Information Update: 21 Apr 2026
At a glance
- Originator Sosei Heptares
- Developer Neurocrine Biosciences; Nxera Pharma
- Class Antipsychotics; Small molecules
- Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M4 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Schizophrenia
Most Recent Events
- 08 Apr 2026 Phase-II clinical trials in Schizophrenia (Treatment experienced) in Bulgaria (PO) (CTIS2025-521868-35-00)
- 22 Dec 2025 Phase-II clinical trials in Schizophrenia (Treatment experienced) in United Kingdom (PO) (NCT07288333)
- 13 Oct 2025 NBI 1117570 is still in phase I trial for Schizophrenia (In volunteers) in the Netherlands (PO) (CTIS2023-508814-40-00)